Novavax (NVAX) EBIT (2010 - 2026)

Novavax's EBIT history runs 17 years deep, the most recent figure standing at -$15.4 million for Q1 2026.

• On a quarterly basis, EBIT fell 102.99% year-over-year to -$15.4 million in Q1 2026; TTM through Mar 2026 was -$78.1 million, a 119.0% decrease from a year earlier, with the FY2025 full-year figure at $452.8 million, up 281.9% from the prior year.
• EBIT retreated to -$15.4 million in Q1 2026 per NVAX's latest filing, from $14.2 million in the prior quarter.
• Across five years, EBIT topped out at $515.5 million in Q1 2025 and bottomed at -$483.0 million in Q2 2022.
• The 5-year median for EBIT is -$127.2 million (2022), against an average of -$60.2 million.
• Across the five-year window, EBIT tumbled 249.44% in 2023 and surged 455.94% in 2025, its largest moves.
• Year by year, EBIT stood at -$243.9 million in 2022, then grew by 24.73% to -$183.6 million in 2023, then increased by 28.59% to -$131.1 million in 2024, then jumped by 110.86% to $14.2 million in 2025, then tumbled by 208.43% to -$15.4 million in 2026.
• Per Business Quant, the three latest NVAX EBIT figures stand at -$15.4 million (Q1 2026), $14.2 million (Q4 2025), and -$178.0 million (Q3 2025).